A Study of PRN1008 in Adult Patients With Immune Thrombocytopenia (ITP)
Status:
Recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This is a 2 part (Part A and B) adaptive, open-label, dose-finding study of PRN1008 in
patients with ITP who are refractory or relapsed with no available and approved therapeutic
options, with a platelet count <30,000/μL on two counts no sooner than 7 days apart in the 15
days before treatment begins. The dose-finding portion of the study has been completed. Part
B treatment dose is 400 mg twice daily.